Skip to main content
Equibles
MYGN logo

MYGN · Myriad Genetics Inc · Metrics

Track MYGN — free

Use MYGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MYGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.63 +0.00 (+0.00%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$634.16M
Shares
95.65M
Volume · Oct 29 414.26K Avg daily vol (3M) 2.63M

MYGN metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.63
Market cap
$634.16M

Price action

20 metrics
Price change (1W)
+19.0%
Price change (30D)
+56.7%
Price change (3M)
+31.5%
Price change (6M)
+41.7%
Price change (YTD)
+7.8%
Price change (1Y)
-18.5%
Trailing year
Price change (5Y)
-79.3%
52-week high
$8.18
52-week low
$2.86
Change from 52-week high
-18.9%
Change from 52-week low
+131.8%
Annualized volatility
86.4%
Annualized volatility (3M)
129.3%
Beta
1.2
RSI (14D)
81.0
Price vs SMA 50
+62.5%
Price vs SMA 200
+44.0%
Avg volume (3M)
2.63M
Relative volume
1.0
Average dollar volume
$10.76M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
95.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 132.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 134.1%
P / book
2.0
reciprocal yield 50.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
78.1
reciprocal yield 1.3%
Earnings yield
-18.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 88.3%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 54.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
68.8%
Operating margin
-12.2%
Trailing 12 months
Net margin
-14.0%
Gross profit (TTM)
$555.20M
Operating profit (TTM)
−$98.60M
Net income (TTM)
−$112.60M
Trailing 12 months
Diluted EPS (TTM)
$-1.20
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$8.61
Gross profit per diluted share (TTM)
$5.92
Operating profit per diluted share (TTM)
$-1.05
EBITDA per diluted share (TTM)
$-0.51
Net income per diluted share (TTM)
$-1.20
Operating cash flow per diluted share (TTM)
$0.09
Free cash flow per diluted share (TTM)
$-1.46
Capital expenditures per diluted share (TTM)
$0.92
R&D per diluted share (TTM)
$1.13
Stock compensation per diluted share (TTM)
$0.31
Book value per share
$3.94

Growth

11 metrics
Revenue growth YoY
-10.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$806.60M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+6.7%
Revenue CAGR (5Y)
+8.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-37.1%
Return on assets
-17.6%
Debt / equity
0.4
Current ratio
2.2
EBITDA (TTM)
−$48.40M
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
-6.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$5.50M
Latest balance sheet
Cash & equivalents
$115.20M
Total assets
$638.90M
Total debt
$120.70M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$7.70M
Capital expenditures (TTM)
$74.60M
R&D (TTM)
$105.80M
SG&A (TTM)
$569.00M
Stock compensation (TTM)
$28.70M
R&D / revenue
13.1%
Stock compensation / revenue
3.6%

Ownership (13F)

9 metrics
13F filers
197
13F filer change QoQ
-7
Institutional ownership
93.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
41.1%
Private-fund adviser ownership
33.9%
Active holders' share change QoQ
-1.3%
Holder tenure
13.5
Price vs estimated holder cost
-25.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
18.2%

Short interest

3 metrics
Short interest
9.7%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
90 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 899923 CUSIP 62855J104 13F (30d) 25 filings 25 filers Visit website Investor relations